Allurion Technologies Inc.

ALUR ·Healthcare, Medical Devices, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022
Operating Activities
Net Income $-28.8M $-7.2M $-82.8M $-37.7M
Depreciation & Amortization $983.0K $997.0K $746.0K $895.0K
Depreciation $1.0M $1.0M $746.0K $875.0K
Amortization — — — —
Stock-Based Compensation $3.1M $3.1M $8.4M $437.0K
Net Cash from Operating Activities $-28.9M $-42.3M $-64.0M $-47.0M
Investing Activities
Capital Expenditures — $611.0K $1.6M $1.6M
Business Acquisitions — — — —
Net Cash from Investing Activities — $-611.0K $-1.6M $-1.6M
Financing Activities
Dividends Paid — — — —
Stock Repurchases — — — —
Net Cash from Financing Activities $19.0M $20.2M $96.0M $30.5M
Net Change in Cash $-10.0M $-22.7M $30.4M $-18.0M
Free Cash Flow — $-42.9M $-65.6M $-48.5M